Neovasc Reducer

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

The Reducer has been added to the European Society of Cardiology Practice Guidelines at the highest recommendation class for therapies addressing refractory angina.   Learn More >

Positive results from the COSIRA clinical trial. Learn More >

Access our library of publications about the ReducerTM  here >

This device is currently only available in the EU.


  • Treats a large and growing population of patients suffering from refractory angina who have limited options
  • Currently CE Marked
  • COSIRA data showed patients treated with Reducer were 2.3 times more likely to see an improvement of two Canadian Cardiovascular Society (CCS) functional classification as compared to the control arm (n = 104, p value = 0.024).


Note: The CCS class is a functional classification used to stratify the severity of angina by evaluating angina symptoms with activity levels. N Eng J Med 2015;372:519-527